Metabotropic glutamate receptor orthosteric ligands and their binding sites

Neuropharmacology. 2022 Feb 15:204:108886. doi: 10.1016/j.neuropharm.2021.108886. Epub 2021 Nov 20.

Abstract

Metabotropic glutamate receptors (mGluRs) have been discovered almost four decades ago. Since then, their pharmacology has been largely developed as well as their structural organization. Indeed mGluRs are attractive therapeutic targets for numerous psychiatric and neurological disorders because of their modulating role of synaptic transmission. The more recent drug discovery programs have mostly concentrated on allosteric modulators. However, orthosteric agonists and antagonists have remained unavoidable pharmacological tools as, although not expected, many of them can reach the brain, or can be modified to reach the brain. This review focuses on the most common orthosteric ligands as well as on the few allosteric modulators interacting with the glutamate binding domain. The 3D-structures of these ligands at their binding sites are reported. For most of them, X-Ray structures or docked homology models are available. Because of the high conservation of the binding site, subtype selective agonists were not easy to find. Yet, some were discovered when extending their chemical structures in order to reach selective sites of the receptors.

Keywords: 3D-structure; Antagonists; Binding site; Orthosteric agonists; Selectivity; Venus flytrap.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Allosteric Regulation
  • Binding Sites
  • Drug Discovery
  • Humans
  • Ligands
  • Molecular Conformation
  • Molecular Targeted Therapy
  • Nervous System Diseases / drug therapy
  • Receptors, Metabotropic Glutamate / agonists*
  • Receptors, Metabotropic Glutamate / chemistry
  • Receptors, Metabotropic Glutamate / metabolism*
  • Receptors, Metabotropic Glutamate / physiology
  • Synaptic Transmission

Substances

  • Ligands
  • Receptors, Metabotropic Glutamate